Media coverage about Surgery Partners (NASDAQ:SGRY) has trended positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Surgery Partners earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.69322061329 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news articles that may have impacted Accern’s scoring:
Several equities analysts have recently weighed in on SGRY shares. ValuEngine downgraded Surgery Partners from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research downgraded Surgery Partners from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Bank of America downgraded Surgery Partners from a “buy” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research report on Wednesday, November 1st. Benchmark set a $19.00 target price on Surgery Partners and gave the company a “buy” rating in a research report on Tuesday, January 30th. Finally, BidaskClub upgraded Surgery Partners from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Three analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Surgery Partners presently has a consensus rating of “Hold” and a consensus price target of $17.86.
Surgery Partners (NASDAQ:SGRY) opened at $14.00 on Tuesday. Surgery Partners has a 1 year low of $7.10 and a 1 year high of $24.05. The company has a market capitalization of $714.47, a P/E ratio of -30.43 and a beta of 2.47. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.92 and a current ratio of 2.09.
Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.07. Surgery Partners had a positive return on equity of 1.03% and a negative net margin of 0.33%. analysts forecast that Surgery Partners will post -0.16 EPS for the current year.
Surgery Partners declared that its Board of Directors has approved a share buyback program on Friday, December 15th that authorizes the company to buyback $50.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its stock is undervalued.
ILLEGAL ACTIVITY NOTICE: “Positive Media Coverage Somewhat Unlikely to Impact Surgery Partners (SGRY) Stock Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/06/positive-media-coverage-somewhat-unlikely-to-impact-surgery-partners-sgry-stock-price.html.
About Surgery Partners
Surgery Partners, Inc is a healthcare services company. The Company operates in three lines of business across the United States: Surgical Facility Services, Ancillary Services and Optical Services. The Company’s Surgical Facility Services segment consists of the operation of ambulatory surgery centers (ASCs) and surgical hospitals, which include its anesthesia services.
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.